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Expression of osteoprotegerin and 
its ligands, RANKL and TRAIL, in 
rheumatoid arthritis
Sara Remuzgo-Martínez1,*, Fernanda Genre1,*, Raquel López-Mejías1,*, Begoña Ubilla1, 
Verónica Mijares1, Trinitario Pina1, Alfonso Corrales1, Ricardo Blanco1, Javier Martín2, 
Javier Llorca3,† & Miguel A. González-Gay1,4,†
Osteoprotegerin (OPG), receptor activator of nuclear factor-ΚB ligand (RANKL) and tumor necrosis 
factor-related apoptosis-inducing ligand (TRAIL) have been involved in rheumatoid arthritis (RA) 
pathophysiology. In this study, we assessed messenger RNA (mRNA) expression of these molecules 
by qPCR in peripheral blood from 26 patients with RA (12 of them with ischemic heart disease –IHD) 
and 10 healthy controls. Correlation coefficients between OPG, RANKL and TRAIL expression levels 
in RA patients and their clinical and demographic characteristics were also evaluated. Whereas OPG 
and OPG/TRAIL ratio expression were significantly increased in RA patients compared to controls 
(fold change = 1.79, p = 0.013 and 2.07, p = 0.030, respectively), RANKL/OPG ratio was significantly 
decreased (fold change = 0.50, p = 0.020). No significant differences were found between patients and 
controls in RANKL and TRAIL expression. Interestingly, TRAIL expression was significantly higher in RA 
patients with IHD compared to those without IHD (fold change = 1.46, p = 0.033). Moreover, biologic 
disease-modifying antirheumatic drugs (DMARDs) significantly decreased RANKL expression in RA 
patients (p = 0.016). Our study supports an important role of OPG and TRAIL in RA. Furthermore, it 
highlights an effect of biologic DMARDs in the modulation of RANKL.
Osteoprotegerin (OPG)/receptor activator of nuclear factor-Κ B ligand (RANKL)/tumor necrosis factor 
(TNF)-related apoptosis-inducing ligand (TRAIL) system has been involved in the pathophysiology of rheuma-
toid arthritis (RA)1,2. OPG is a soluble glycoprotein, member of the TNF-receptor superfamily and an inhibitor 
of two cytokines belonging to the TNF ligand family, RANKL and TRAIL3. RANKL functions as a key factor for 
osteoclastogenesis, since the binding with its receptor, receptor activator of nuclear factor-Κ B (RANK), favors 
the activation of osteoclasts and bone resorption. OPG reduces RANKL-RANK interactions and thus inhibits 
osteoclastogenesis3. In this regard, RANKL/OPG ratio plays an important role regulating bone homeostasis in 
RA, a disease characterized by bone and cartilage destruction1,4. Furthermore, a protective role in RA has been 
shown for TRAIL, an anti-inflammatory molecule mainly known as inductor of apoptosis in tumor cells. Thus, 
TRAIL could be involved in the regulation of the systemic inflammatory autoimmune response produced by the 
disease2. However, increasing evidence suggest it could be a pleiotropic cytokine with a dual function5. Since 
OPG can bind to TRAIL inhibiting their function, it has been proposed that the OPG/TRAIL ratio could also be 
involved in RA pathogenesis6.
It is well known that RA patients have an accelerated atherosclerotic process, leading to an increased risk of 
cardiovascular (CV) disease, including ischemic heart disease (IHD)7. In this sense, OPG/RANKL/TRAIL system 
has also been related to atherosclerosis and CV disease8. Due to the important role that these molecules play in 
CV disease, they have been proposed as potential biomarkers of CV disease8,9.
Previously, our group reported that OPG serum levels were associated with CV disease in RA patients10. 
Therefore, to confirm the role of OPG and its ligands, RANKL and TRAIL, in the pathophysiology of RA, we 
determined for the first time the differential gene expression of these molecules in peripheral blood from patients 
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with RA, with and without IHD, and healthy controls. Changes in expression level of these molecules and its 
correlation with clinical and demographic characteristics of RA patients will also be useful to elucidate this role.
Taking into account that both RA and CV disease are inflammatory systemic diseases, the assessment of OPG, 
RANKL and TRAIL expression at a systemic level (blood) is of main importance.
Patients and Methods
Patients and controls. For experiments involving humans and the use of human blood samples, all 
the methods were carried out in accordance with the approved guidelines and regulations, according to the 
Declaration of Helsinki. All experimental protocols were approved by the Ethics Committee of clinical research 
of Cantabria (CEIC-C, Number of reference 14/2012). Informed consent was obtained from all subjects.
Twenty-six RA patients, 12 of them with IHD, and ten healthy controls matched for age and sex were recruited 
from Hospital Universitario Marqués de Valdecilla (Santander, Cantabria, Spain). All RA patients met the 2010 
American College of Rheumatology classification criteria for RA11. We recorded the main demographic and clin-
ical characteristics of patients, measured the erythrocyte sedimentation rate (ESR), C-reactive protein (CRP) and 
lipids, and calculated the Disease Activity Score in 28 joints (DAS28)-CRP and –ESR at the time of assessment. 
The presence of IHD and traditional CV risk factors were defined as previously reported10. The characteristics of 
the RA patients and controls included in this study have previously been described12.
Blood RNA extraction. As we previously described, total RNA was isolated from peripheral blood samples 
according to the manufacturer’s protocol using NucleoSpin RNA Blood Midi Kit (Macherey-Nagel)12. Samples 
were concentrated using GeneJET RNA Cleanup and Concentration Micro Kit (Thermo Scientific) and stored 
at − 80 °C until further processing.
Quantitative real-time polymerase chain reaction (PCR). For each sample, 1 μ g of total RNA was 
reverse transcribed into cDNA using iScriptTM Advanced cDNA Synthesis Kit for RT-qPCR (Bio-Rad, Hercules, 
CA, USA). 20 ng of cDNA was used for quantitative real-time PCR (qPCR), using SsoAdvancedTM Universal 
SYBR® Green Supermix (Bio-Rad, Hercules, CA, USA). Primers for amplification of OPG, RANKL, TRAIL, 
beta-actin and GAPDH were acquired from PrimePCR Assays, Bio-Rad, Hercules, CA, USA. All samples were 
assayed in triplicate and controls were included in each reaction. qPCRs were performed in a 7900 HT real-time 
instrument (Applied Biosystems, Foster City, CA, USA) using the following conditions: stage 1: 95 °C for 2 min, 
stage 2: 95 °C for 5 sec followed by 60 °C for 30 sec repeated for 45 cycles. The threshold cycle (Ct) was manually 
established and recorded by the SDS 2.2.2 software (Applied Biosystems, Foster City, CA, USA). The relative OPG, 
RANKL and TRAIL messenger RNA (mRNA) expression was analyzed by the comparative Ct method, using 
beta-actin and GAPDH as housekeeping genes12. Normalized expression levels were obtained for each sample 
and the RANKL/OPG and OPG/TRAIL ratios were calculated with these data. Mean values were determined 
for each study group and fold-change (changed amount of expression) was calculated by comparing the means 
between different groups. A fold-change value less than 1 indicates negative or down-regulation of the study gene. 
A fold-change value greater than 1 indicates positive or up-regulation.
OPG, RANKL and TRAIL serum levels by enzyme-linked immunosorbent assay (ELISA). OPG 
levels were measured as previously described10. Concentrations of free soluble RANKL and TRAIL were also 
determined by ELISA, using kits from Biomedica (BI-20462) and R&D Systems (DTRL00), respectively, accord-
ing to the manufacturer’s instructions. All samples were analyzed in duplicate.
Statistical analysis. Results were expressed as mean ± standard deviation (SD). Normalized expression val-
ues and protein levels obtained for each sample were analyzed by GraphPad Prism® 3.0 (GraphPad Software, San 
Diego, CA, USA) using nonparametric Mann-Withney U test to compare two study groups. A p value < 0.05 was 
considered statistically significant.
OPG, RANKL and TRAIL expression among patients with RA and controls was first compared by analysis of 
covariance (ANCOVA), with adjustment for age, sex, and traditional CV risk factors.
Partial correlations of demographic and clinical characteristics in RA patients with their relative OPG, RANKL 
and TRAIL mRNA levels were performed after adjusting for age at the time of the study, sex, and classic CV risk 
factors via estimation of the Pearson partial correlation coefficient (r). The same statistical analysis was con-
ducted to analyze whether OPG expression levels were associated with RANKL and TRAIL mRNA expression. A 
p value < 0.05 was considered statistically significant. These analyses were performed using Stata 12/SE 
(StataCorp, College Station, TX).
Results
OPG, RANKL and TRAIL expression in RA. Expression of the OPG gene was significantly increased in 
RA patients compared to controls (fold change = 1.79, p = 0.013, Table 1). In this regard, patients with RA had 
a mean OPG expression of 6.68 ± 3.69 whereas controls had a mean OPG expression of 3.74 ± 2.00 (Table 1 and 
Fig. 1a). However, no significant differences were found between patients and controls in RANKL and TRAIL 
mRNA expression (Table 1). A decreased RANKL/OPG ratio and an increased OPG/TRAIL ratio was observed 
in patients compared to controls (fold change = 0.50 and 2.07, respectively). These differences in expression were 
statistically significant (p = 0.020 and p = 0.030, respectively, Table 1).
When RA patients were stratified according to the presence or absence of IHD, we disclosed that the rel-
ative TRAIL mRNA expression was significantly higher in RA patients with compared to those without IHD 
(3.58 ± 1.55 vs 2.45 ± 1.19, fold change = 1.46, p = 0.033, Fig. 1b). However, no significant differences were found 
in OPG and RANKL mRNA levels or in RANKL/OPG and OPG/TRAIL ratios between these two groups (data 
not shown).
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Association of OPG, RANKL and TRAIL mRNA expression with clinical and demographic char-
acteristics in RA patients. An inverse association was found between OPG expression and total cholesterol 
(r = − 0.48, p = 0.040). Additionally, a negative correlation was observed between RANKL expression and CRP 
(r = − 0.52, p = 0.024) and DAS28 CRP (r = − 0.56, p = 0.014). Interestingly, RA patients undergoing treatment 
with biologic disease-modifying antirheumatic drugs (DMARDs) showed a statistically significant decrease of 
RANKL expression (r = − 0.54, p = 0.016). Regarding TRAIL, we disclosed a positive correlation with RA disease 
duration (r = 0.46, p = 0.047) and CRP (r = 0.58, p = 0.010).
Influence of OPG expression on its ligands. No association was found between relative OPG mRNA 
expression and RANKL or TRAIL mRNA levels (p = 0.89 and p = 0.85, respectively) in RA patients.
OPG, RANKL and TRAIL serum levels in RA. ELISA was performed in order to provide supplementary 
information on the OPG, RANKL and TRAIL mRNA expression and the corresponding protein levels. OPG 
serum levels were significantly increased in RA patients compared to controls (9.06 ± 6.00 vs 3.85 ± 1.51 ng/ml, 
mRNA expression (normalized 




n = 26 p value
OPG 3.74 ± 2.00 6.68 ± 3.69 0.013
RANKL 3.67 ± 0.91 3.48 ± 1.41 0.68
TRAIL 3.20 ± 1.30 2.97 ± 1.46 0.51
RANKL/OPG ratio 1.33 ± 0.95 0.67 ± 0.42 0.020
OPG/TRAIL ratio 1.36 ± 0.77 2.81 ± 2.18 0.030
Table 1.  OPG, RANKL, TRAIL and RANKL/OPG and OPG/TRAIL ratios mRNA expression in controls 
and RA patients. Values are given as mean ± SD. Significant results are highlighted in bold (p < 0.05).
Figure 1. Increased OPG mRNA expression in patients with RA and TRAIL mRNA expression in RA 
patients with IHD. OPG and TRAIL expression was normalized to two housekeeping genes (beta-actin and 
GAPDH). (a) Differential expression of relative OPG mRNA was analyzed between control group (n = 10) and 
RA patients (n = 26). (b) Differential expression of relative TRAIL mRNA was analyzed between RA patients 
stratified according to the presence (n = 12) or absence of IHD (n = 14). Each bar represents mean value ± SD 
obtained for each sample in triplicate.
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p = 0.002). No significant differences were found between patients and controls in RANKL and TRAIL 
concentrations.
Discussion
Several molecules have been implicated in the pathogenesis of both RA and CV disease13. In this regard, the OPG/
RANKL/TRAIL system has been linked to bone loss in RA and CV risk1,6,8. To further study the involvement of 
this system in RA at the gene expression level, we evaluated the OPG, RANKL and TRAIL mRNA levels in periph-
eral blood from patients with RA and their relationship with clinical and demographical characteristics of RA 
disease. Furthermore, we studied its potential association with IHD in patients with RA.
Previously, it has been reported that the expression of many cytokines and growth factors is up- or 
down-regulated in both peripheral blood and local joints in patients with RA14. In this regard, circulating (or 
peripheral) blood cells from RA patients have been used in previous studies to assess the OPG/RANKL/TRAIL 
gene expression for prognosis or diagnosis of RA14,15. In addition, considering that RA and CV disease affect 
multiple tissues at a systemic level, we believe that the assessment of the role of these molecules in circulation is 
very relevant.
OPG regulates bone homeostasis upon binding to RANKL and also participates in the pathogenesis of ath-
erosclerosis and CV diseases8. We previously described that OPG concentrations are independently associated 
with endothelial activation, carotid atherosclerosis and established CV disease in RA10,16. In the present study, we 
observed that the expression of OPG was up-regulated in RA patients, supporting its pivotal role in the pathogen-
esis of RA. Moreover, the increase in OPG serum levels disclosed in our patients with RA enables us to confirm 
that the upregulation of OPG at a systemic level leads to a high release of OPG protein in serum. In addition, OPG 
mRNA levels were inversely associated with total cholesterol. This finding is in line with former results of our 
group performed in RA and ankylosing spondylitis patients, which disclosed a negative correlation between OPG 
and total and LDL cholesterol, even if they were assessed regarding serum/plasma concentrations16,17. However, 
in another study from our group we could not find an association between OPG levels and cholesterol from a 
different cohort of patients with RA10. These results may appear to be contradictory at first glance. However, we 
believe that potential associations observed between a clinical characteristic or disease with gene expression at 
mRNA level does not necessarily have to be reflected in protein concentrations. Nevertheless, further studies with 
a larger number of samples should be performed to elucidate these discrepancies.
Regarding RANKL mRNA expression, no significant differences were found between our patients and con-
trols. The same finding was previously shown in synovial fluid-neutrophils from RA patients compared to normal 
blood-neutrophils from healthy individuals18. In addition, we disclosed a negative association between RANKL 
mRNA and treatment with biologic DMARDs. Therefore, it is plausible to think that RANKL expression is being 
modulated at a transcriptional level by these drugs. Accordingly, biologic and synthetic DMARDs also decreased 
RANKL mRNA in fibroblasts from RA patients19,20.
TRAIL is another molecule involved in this system. It has also been associated with atherosclerosis and CV 
disease2,8. With respect to this, we disclosed a significant up-regulation of this gene in patients with IHD com-
pared to those without IHD. In keeping with this result, TRAIL concentrations were found to be increased in 
RA patients with heart failure21. Since TRAIL is an anti-inflammatory molecule, the high expression observed in 
RA patients with IHD could be the result of a compensatory mechanism to limit the potential pro-inflammatory 
effects triggered by other cytokines. However, depending on the context, the role of TRAIL is still confusing5. 
Consequently, our data suggest that high expression of TRAIL may be a potential predictor of CV disease in RA 
patients. In addition, the positive relationship between TRAIL mRNA expression and both CRP concentrations 
and RA disease duration reinforces our hypothesis. In this regard, CRP, involved in systemic inflammation and 
CV disease, has also been related to TRAIL serum levels in other chronic inflammatory arthritis, such as psoriatic 
arthritis22.
Finally, the upregulation of OPG observed in our RA patients led to an increased OPG/TRAIL ratio. Since 
TRAIL mRNA was associated with IHD in our study, this ratio may also play an important role in the develop-
ment CV disease. This finding is agreement with Secchiero et al., who disclosed an increased in OPG/TRAIL ratio 
levels in patients with acute myocardial infarction who developed heart failure23.
Our study supports an important role of OPG and TRAIL in RA. Furthermore, it highlights an effect of bio-
logic DMARDs in the modulation of RANKL.
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